Gabexate mesilate vials 100 mg for pancreatitis and disseminated intravascular coagulation (DIC)

General information on Japanese Gabexate mesilate vials 100 mg for pancreatitis and disseminated intravascular coagulation (DIC)

Package details: 10 vials

Manufacturer: Nichi-Iko Pharmaceutical Co., Ltd., Japan

Active ingredient: gabexate mesilate (chemical formula C16H23N3O4)

Medical effect: Gabexate mesilate vials are effective for the treatment of following:

• acute pancreatitis associated with protease (trypsin, kallikrein, plasmin, etc.) deviation,
• acute exacerbation of chronic recurrent pancreatitis,
• postoperative acute pancreatitis,
• disseminated intravascular coagulation (DIC).

Contraindications and precautions: do not use for pregnant and breastfeeding women.

If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Dosage and administration

For acute pancreatitis, acute exacerbation of chronic recurrent pancreatitis, postoperative acute pancreatitis: inject this medicine intravenously.

For disseminated intravascular coagulation (DIC): the daily dose is given as a continuous intravenous infusion over 24 hours.

The length of the course of treatment is to be decided by doctor in charge according to patient's symptoms.

How effective are Gabexate mesilate vials 100 mg from Japan for pancreatitis and disseminated intravascular coagulation (DIC)?

Gabexate mesilate is a  synthetic protease inhibitor. It works by inhibiting both coagulation and cytokine production by monocytes. As the result, Gabexate mesilate ampoules improve organ disorders and bleeding tendencies caused by blood clots in blood vessels and relieve such symptoms as pain caused by inflammation of the pancreas.

Who should take Gabexate mesilate ampoules 100 mg from Japan?

Gabexate mesilate ampoules are effective for the treatment of disseminated intravascular coagulation (DIC) and various forms of pancreatitis, including acute pancreatitis associated with protease deviation, acute exacerbation of chronic recurrent pancreatitis and postoperative acute pancreatitis. Studies showed that treatment with gabexate mesilate significantly reduces the incidence of complications requiring surgery and of complications in general in patients with acute pancreatitis (A. Messori, , R. Rampazzo et al. “Effectiveness of gabexate mesilate in acute pancreatitis. A metaanalysis”.  Digestive Diseases and Sciences, 1995, 40(4): 734-738).